Skip to main content
Top
Published in: Annals of Hematology 3/2021

01-03-2021 | Graft-Versus-Host Disease | Original Article

Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level

Authors: Warren Fingrut, Arjun Law, Wilson Lam, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Dennis Dong Hwan Kim

Published in: Annals of Hematology | Issue 3/2021

Login to get access

Abstract

Allogeneic hematopoietic stem cell transplantation (HCT) is associated with significant morbidity and mortality. Elevated pre-transplant ferritin level (ferritinPre-HCT) is reported to be associated with increased mortality following HCT. The present study attempted to determine whether post-transplant ferritin level (ferritinPost-HCT) is associated with outcomes post-HCT, especially in the subgroups which developed acute or chronic graft-versus-host disease (GVHD). Out of 229 patients with serum ferritin level measured post-HCT, median ferritinPost-HCT was 2178 ng/mL. Patients were stratified into low- or high-risk groups using recursive partitioning, based on ferritinPost-HCT (≤ 3169 vs > 3169 ng/mL) and ferritinPre-HCT (≤ 669 vs > 669 ng/mL). Compared to the low ferritinPost-HCT group, the high ferritinPost-HCT group had lower 3-year overall survival (OS) (40.0% vs 66.7%, p < 0.001) and higher non-relapse mortality (NRM) (48.6% vs 17.8%, p < 0.001), but no difference in relapse (10.5% vs 19.7%, p = 0.079). Multivariate analysis confirmed ferritinPost-HCT as an independent prognostic factor for OS (p = 0.001, HR = 2.323) and NRM (p < 0.001, HR = 3.905). However, ferritinPre-HCT did not stratify well for OS or NRM. FerritinPost-HCT was also found to be an independent prognostic marker for OS and NRM in the subgroups which developed GVHD. In our cohort, high ferritinPost-HCT levels were significantly associated with decreased OS and increased NRM independent of ferritinPre-HCT or GVHD. Additional studies including larger sample sizes and prospective investigation are warranted to clarify the prognostic significance and pathophysiology of pre- and post-transplant hyperferritinemia.
Appendix
Available only for authorised users
Literature
4.
go back to reference Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377:2565–2579CrossRef Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377:2565–2579CrossRef
5.
go back to reference Pond G, Lipton J, Messner H (2006) Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. Biol Blood Marrow Transpl 12:422–429CrossRef Pond G, Lipton J, Messner H (2006) Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. Biol Blood Marrow Transpl 12:422–429CrossRef
6.
go back to reference Gupta, V., Daly, A., Lipton, J. & Al., E. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transpl. 11, 764–72 (2005) Gupta, V., Daly, A., Lipton, J. & Al., E. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transpl. 11, 764–72 (2005)
7.
go back to reference Kiss, T., Panzarella, T., Messner, H. & Al., E. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin’s lymphoma. Bone Marrow Transpl. 31, 73–8 (2003) Kiss, T., Panzarella, T., Messner, H. & Al., E. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin’s lymphoma. Bone Marrow Transpl. 31, 73–8 (2003)
8.
go back to reference Messner H (2002) Long-term outcome of allogeneic transplants in acute myeloid leukemia. Leukemia 16:751–752CrossRef Messner H (2002) Long-term outcome of allogeneic transplants in acute myeloid leukemia. Leukemia 16:751–752CrossRef
9.
go back to reference Kim, D., Messner, H., Minden, M. & Al., E. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl. Infect Dis. 10, 90–8 (2008) Kim, D., Messner, H., Minden, M. & Al., E. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl. Infect Dis. 10, 90–8 (2008)
10.
go back to reference Kim, D., Jamal, N., Saragosa, R. & Al., E. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transpl. 13, 1233–43 (2007) Kim, D., Jamal, N., Saragosa, R. & Al., E. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transpl. 13, 1233–43 (2007)
11.
go back to reference Armand, P., Kim, H., Logan, B. & Al., E. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 123, 3664–3671 (2014) Armand, P., Kim, H., Logan, B. & Al., E. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 123, 3664–3671 (2014)
12.
go back to reference Przepiorka, D., Weisdorf, D., Martin, P. & Al., E. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl. 15, 825–8 (1995) Przepiorka, D., Weisdorf, D., Martin, P. & Al., E. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl. 15, 825–8 (1995)
13.
go back to reference Filipovich & Al., E. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transpl. 11, 945–956 (2005) Filipovich & Al., E. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transpl. 11, 945–956 (2005)
14.
go back to reference Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48:452–458CrossRef Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48:452–458CrossRef
15.
go back to reference Meyer, S., O’Meara, A., Buser, A. & Al., E. Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 19, 440–444 (2013) Meyer, S., O’Meara, A., Buser, A. & Al., E. Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 19, 440–444 (2013)
16.
go back to reference Goldberg, S., Elmann, M., Kaminetzky, M. & Al., E. One-year post-transplant serum ferritin level is a predictor of long-term survival following allogeneic transplantation. Blood 116, 3453 (2010) Goldberg, S., Elmann, M., Kaminetzky, M. & Al., E. One-year post-transplant serum ferritin level is a predictor of long-term survival following allogeneic transplantation. Blood 116, 3453 (2010)
17.
go back to reference Tachibana, T., Tanaka, M., Numata, A. & Al., E. Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients. Leuk. Lymphoma 55, 1350–1356 (2014) Tachibana, T., Tanaka, M., Numata, A. & Al., E. Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients. Leuk. Lymphoma 55, 1350–1356 (2014)
19.
go back to reference Brissot E, Savani BN, Mohty M (2012) Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation. Semin Hematol 49:35–42CrossRef Brissot E, Savani BN, Mohty M (2012) Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation. Semin Hematol 49:35–42CrossRef
22.
go back to reference Inati A, Kahale M, Sbeiti N, Cappellini MD, Taher AT, Koussa S, Nasr TA, Musallam KM, Abbas HA, Porter JB (2017) One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatr Blood Cancer 64:188–196. https://doi.org/10.1002/pbc.26213CrossRefPubMed Inati A, Kahale M, Sbeiti N, Cappellini MD, Taher AT, Koussa S, Nasr TA, Musallam KM, Abbas HA, Porter JB (2017) One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatr Blood Cancer 64:188–196. https://​doi.​org/​10.​1002/​pbc.​26213CrossRefPubMed
24.
go back to reference Tachibana, T., Takana, M., Motohashi, K. & Al., E. Clinical significance of serum ferritin compared to liver iron content, measured using magnetic resonance imaging, after allogeneic hematopoietic cell transplantation. J. Hematop. Cell Transplant. 4, 47–51 (2015) Tachibana, T., Takana, M., Motohashi, K. & Al., E. Clinical significance of serum ferritin compared to liver iron content, measured using magnetic resonance imaging, after allogeneic hematopoietic cell transplantation. J. Hematop. Cell Transplant. 4, 47–51 (2015)
25.
go back to reference Mahindra A, Bolwell B (2009) Sobecks, R. & Al., E. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft vs host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Brit J Haematol 146:310–316CrossRef Mahindra A, Bolwell B (2009) Sobecks, R. & Al., E. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft vs host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Brit J Haematol 146:310–316CrossRef
26.
go back to reference Sakamoto S, Kawabata H (2013) Kanda, J. & Al., E. Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Int J Hematol 97:109–116CrossRef Sakamoto S, Kawabata H (2013) Kanda, J. & Al., E. Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Int J Hematol 97:109–116CrossRef
27.
go back to reference Tanaka, M., Kanamori, H., Matsumoto, K. & Al., E. Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy. Bone Marrow Transpl. 50, 727–733 (2015) Tanaka, M., Kanamori, H., Matsumoto, K. & Al., E. Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy. Bone Marrow Transpl. 50, 727–733 (2015)
28.
go back to reference Wingard, J., Piantadosi, S., Vogelsang, G. & Al., E. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74, 1428–1435 (1989) Wingard, J., Piantadosi, S., Vogelsang, G. & Al., E. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74, 1428–1435 (1989)
29.
go back to reference Stewart, B., Storer, B., Storek, J. & Al., E. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104, 3501–3506 (2004) Stewart, B., Storer, B., Storek, J. & Al., E. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104, 3501–3506 (2004)
30.
go back to reference Sullivan, K., Witherspoon, R., Storb, R. & Al., E. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 72, 546–554 (1988) Sullivan, K., Witherspoon, R., Storb, R. & Al., E. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 72, 546–554 (1988)
31.
go back to reference Akpek G, Zahurak M (2001) Piantadosi, S. & Al., E. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97:1219–1226CrossRef Akpek G, Zahurak M (2001) Piantadosi, S. & Al., E. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97:1219–1226CrossRef
32.
go back to reference Arora, M., Burns, L., Davies, S. & Al., E. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transpl. 9, 38–45 (2003) Arora, M., Burns, L., Davies, S. & Al., E. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transpl. 9, 38–45 (2003)
33.
go back to reference Kuzmina Z, Eder S (2012) Bohm, A. & Al., E. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 26:746–756CrossRef Kuzmina Z, Eder S (2012) Bohm, A. & Al., E. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 26:746–756CrossRef
34.
go back to reference Arora, M., Klein, J., Weisdorf, D. & Al., E. Chronic GVHD risk score: a center for International Blood and Marrow Transplant Research analysis. Blood 117, 6714–6720 (2011) Arora, M., Klein, J., Weisdorf, D. & Al., E. Chronic GVHD risk score: a center for International Blood and Marrow Transplant Research analysis. Blood 117, 6714–6720 (2011)
35.
go back to reference Inamoto, Y., Kim, D., Storer, B. & Al., E. Application of CIBMTR risk score to NIH chronic GVHD at individual centers. Blood 123, 453–455 (2014) Inamoto, Y., Kim, D., Storer, B. & Al., E. Application of CIBMTR risk score to NIH chronic GVHD at individual centers. Blood 123, 453–455 (2014)
36.
go back to reference Arora M, Hemmer M, Ahn K et al (2015) Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biol Blood Marrow Transpl. 2:640–645CrossRef Arora M, Hemmer M, Ahn K et al (2015) Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biol Blood Marrow Transpl. 2:640–645CrossRef
37.
go back to reference Moon, J., Hamad, N., Sohn, S. & Al., E. Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. Ann. Hematol. 96, 805–815 (2017) Moon, J., Hamad, N., Sohn, S. & Al., E. Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. Ann. Hematol. 96, 805–815 (2017)
Metadata
Title
Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level
Authors
Warren Fingrut
Arjun Law
Wilson Lam
Fotios V. Michelis
Auro Viswabandya
Jeffrey H. Lipton
Rajat Kumar
Jonas Mattsson
Dennis Dong Hwan Kim
Publication date
01-03-2021
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-04363-1

Other articles of this Issue 3/2021

Annals of Hematology 3/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.